EA200900270A1 - Системы регулируемого высвобождения и способ их приготовления - Google Patents

Системы регулируемого высвобождения и способ их приготовления

Info

Publication number
EA200900270A1
EA200900270A1 EA200900270A EA200900270A EA200900270A1 EA 200900270 A1 EA200900270 A1 EA 200900270A1 EA 200900270 A EA200900270 A EA 200900270A EA 200900270 A EA200900270 A EA 200900270A EA 200900270 A1 EA200900270 A1 EA 200900270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
layer
pharmaceutically acceptable
preparation
systems
active substances
Prior art date
Application number
EA200900270A
Other languages
English (en)
Inventor
Нантарат Пирнчоб
Томас Фридль
Карл Герхард Вагнер
Флориан Зоммер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200900270A1 publication Critical patent/EA200900270A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

В заявке описана фармацевтическая система регулируемого высвобождения, предназначенная для введения, предпочтительно для перорального введения, активных веществ, обладающих зависящими от рН растворимостями, включающая: а) материал ядра, включающий или содержащий один или большее количество фармацевтически приемлемых модификаторов рН; b) необязательно изолирующий слой, с) первый слой, включающий или содержащий один или большее количество фармацевтически приемлемых не растворимых в воде полимеров; d) второй слой, включающий или содержащий по меньшей мере одно активное вещество, обладающее зависящей от рН растворимостью; е) третий слой, включающий или содержащий один или большее количество фармацевтически приемлемых полимеров, содержащих анионогенные или неионогенные группы; и f) необязательно четвертый слой предпочтительно в виде наружного слоя покрытия. Обеспечивается не зависящий от рН профиль высвобождения активных веществ, обладающих зависящими от рН характеристиками растворимости in vitro и in vivo.
EA200900270A 2006-08-25 2007-08-10 Системы регулируемого высвобождения и способ их приготовления EA200900270A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06017754 2006-08-25
PCT/EP2007/058302 WO2008022932A2 (en) 2006-08-25 2007-08-10 Controlled release system and method for manufacturing the same

Publications (1)

Publication Number Publication Date
EA200900270A1 true EA200900270A1 (ru) 2009-08-28

Family

ID=38596345

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900270A EA200900270A1 (ru) 2006-08-25 2007-08-10 Системы регулируемого высвобождения и способ их приготовления

Country Status (19)

Country Link
US (1) US8512748B2 (ru)
EP (1) EP2056797A2 (ru)
JP (1) JP5220746B2 (ru)
KR (1) KR20090045945A (ru)
CN (2) CN101505736A (ru)
AR (1) AR062321A1 (ru)
AU (1) AU2007287639A1 (ru)
BR (1) BRPI0716436B8 (ru)
CA (1) CA2661613C (ru)
CL (1) CL2007002358A1 (ru)
CO (1) CO6150131A2 (ru)
EA (1) EA200900270A1 (ru)
IL (1) IL197129A (ru)
MX (1) MX2009002031A (ru)
NO (1) NO20090100L (ru)
PE (1) PE20080738A1 (ru)
TW (1) TW200817053A (ru)
WO (1) WO2008022932A2 (ru)
ZA (1) ZA200810781B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
RU2445095C2 (ru) * 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
CN101884626A (zh) * 2004-08-13 2010-11-17 贝林格尔.英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858516A1 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
EP1904182A2 (en) * 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
WO2006125042A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
CA2641665A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
EP2021006B1 (en) * 2006-05-09 2015-08-12 Sprout Pharmaceuticals, Inc. Use of flibanserin for the treatment of post-menopausal sexual desire disorders
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CA2661613C (en) 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
JP2010513390A (ja) 2006-12-20 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
WO2009118321A1 (de) * 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von säurepellets
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
SI2542224T1 (sl) * 2010-03-01 2014-10-30 Ratiopharm Gmbh Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
WO2012006334A1 (en) * 2010-07-09 2012-01-12 Synthes Usa, Llc Self-detaching layer for easy implant removal
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
EP2861081A4 (en) * 2012-06-14 2016-03-02 Allied Blending & Ingredients Inc METHOD OF TREATING ANTIAGROGRAMMER OF A FRAGMENTED CHEESE PRODUCT AND COMPOSITIONS THEREOF
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
BR112015010704B8 (pt) * 2012-11-12 2022-06-14 New Jersey Inst Technology Partícula compósita, e, processo para preparar uma partícula compósita
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
GB201416293D0 (en) 2014-09-15 2014-10-29 Solvotrin Therapeutics Ltd Methods and preparations
SG10201912713YA (en) 2014-11-14 2020-02-27 Gemphire Therapeutics Inc PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
EP3167879A1 (en) * 2015-11-10 2017-05-17 Evonik Technochemie GmbH Gastric retention active delivery systems
US9668991B1 (en) * 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
PE20181955A1 (es) * 2016-03-15 2018-12-17 Solvotrin Therapeutics Ltd Composiciones y metodos para aumentar la ingesta de hierro en un mamifero
US11033039B2 (en) 2017-04-26 2021-06-15 Allied Blending LP Methods for treating a divided cheese product and compositions thereof
WO2018209257A1 (en) * 2017-05-11 2018-11-15 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
CN110251475B (zh) * 2019-07-25 2021-07-16 沈阳信康药物研究有限公司 一种帕利哌酮片剂及其制备方法
US10624361B1 (en) 2019-09-20 2020-04-21 Allied Blending LP Methods for treating a divided cheese product and compositions thereof
KR20220070473A (ko) * 2019-09-27 2022-05-31 허큘레스 엘엘씨 이산화티타늄 비함유 백색 필름 코팅 조성물, 그를 제조하는 방법 및 그의 사용 방법

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
IL57569A0 (en) 1978-06-20 1979-10-31 Synthelabo Phenylpiperazine derivative,their preparation and pharmaceutical compositions containing them
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
IT1176613B (it) 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
NL8601494A (nl) 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
DE3620643A1 (de) 1985-06-22 1987-01-22 Sandoz Ag Thiazole, ihre herstellung und verwendung
GB8601160D0 (en) 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
WO1992002215A1 (en) 1990-08-09 1992-02-20 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
KR950009102B1 (ko) 1990-08-24 1995-08-14 신에쯔 케미칼 고오교 가부시끼가이샤 제제필름 코팅용기제 및 그 제조방법
NZ241613A (en) 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
FR2675800A1 (fr) 1991-04-26 1992-10-30 Rhone Poulenc Rorer Sa Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2707294B1 (fr) 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ES2163506T3 (es) 1994-06-14 2002-02-01 Pfizer Derivados de bencimidazolona con actividad dopaminergica central.
HU227759B1 (en) 1994-08-23 2012-02-28 Smithkline Beecham Plc Improved pharmaceutical formulations containing ibuprofen and codeine
ATE247114T1 (de) 1994-09-12 2003-08-15 Lilly Co Eli Serotonergische modulatoren
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
GB9613423D0 (en) 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
DE69729950T2 (de) * 1996-11-06 2005-07-28 Wockhardt Europe Ltd. Arzneimittel-Zuführsystem mit verzögerter Freisetzung für säurelabile Arzneistoffe
JP2001504851A (ja) 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
GB9706089D0 (en) 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20040023948A1 (en) 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
WO1998056360A2 (en) 1997-06-11 1998-12-17 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
CH692199A8 (fr) 1997-10-09 2002-06-14 Cermol S.A. Composes pyridiques et compositions pharmaceutique
JP3724157B2 (ja) 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AU4068599A (en) 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO1999059593A1 (en) 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
US20020151543A1 (en) 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
UA67802C2 (ru) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
EP1173168A2 (en) 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
WO2002000654A1 (en) 2000-06-28 2002-01-03 Pfizer Products Inc. Melanocortin receptor ligands
DE60123643T2 (de) 2000-09-19 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
NZ525086A (en) 2000-11-22 2006-07-28 Abbott Lab The use of selective dopamine D4 receptor agonists for treating sexual dysfunction
GB0105893D0 (en) 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
EP1373192A1 (en) 2001-03-28 2004-01-02 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
DE60121301T2 (de) 2001-05-11 2007-07-19 Beck, Jürgen, Dr. Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
ATE411021T1 (de) 2001-07-18 2008-10-15 Merck & Co Inc Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten
JP4272056B2 (ja) 2001-07-30 2009-06-03 スペクトラム・ファーマシューティカルス・インコーポレーテッド アリールピペラジンに連結したテトラヒドロインドロン及びプリン誘導体
EP1414816B1 (en) 2001-08-02 2005-02-09 BIDACHEM S.p.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
MXPA04011487A (es) 2002-05-22 2005-02-14 Boehringer Ingelheim Pharma Nuevas composiciones farmaceuticas que contienen flibanserina polimorfo a.
AU2003236947A1 (en) * 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
GB0225908D0 (en) 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004063864A2 (en) 2003-01-06 2004-07-29 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
CN1777868A (zh) * 2003-04-24 2006-05-24 国际商业机器公司 可执行文件的创建
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
MXPA06000623A (es) 2003-07-16 2006-04-11 Pfizer Tratamiento de la disfuncion sexual.
WO2005044238A1 (en) 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Modified release solid dosage form of amphetamine salts
US20050239798A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
RU2445095C2 (ru) 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
US20060014757A1 (en) 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
EP1858516A1 (en) 2005-03-04 2007-11-28 Boehringer Ingelheim International GmbH Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096434A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) 2005-05-06 2008-04-02 Boehringer Ingelheim International GmbH Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
EP1888070A1 (en) 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
WO2006125042A1 (en) 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
HU227490B1 (en) * 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007090091A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
CA2641917A1 (en) 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
WO2007096300A1 (en) 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of urinary incontinence
WO2007099070A1 (en) 2006-02-28 2007-09-07 Boehringer Ingelheim International Gmbh Treatment of prevention of valvular heart disease with flibanserin
EP2021006B1 (en) 2006-05-09 2015-08-12 Sprout Pharmaceuticals, Inc. Use of flibanserin for the treatment of post-menopausal sexual desire disorders
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EP2043649A2 (en) 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
WO2008006838A1 (en) 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
JP2008040352A (ja) * 2006-08-09 2008-02-21 Seiko Epson Corp 液体現像剤、液体現像剤の製造方法、画像形成方法、および画像形成装置
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2661613C (en) 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
WO2008116890A2 (en) 2007-03-28 2008-10-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders

Also Published As

Publication number Publication date
CA2661613A1 (en) 2008-02-28
CN101505736A (zh) 2009-08-12
CL2007002358A1 (es) 2008-04-18
AR062321A1 (es) 2008-10-29
MX2009002031A (es) 2009-03-06
BRPI0716436B1 (pt) 2020-05-19
KR20090045945A (ko) 2009-05-08
CA2661613C (en) 2016-01-26
AU2007287639A1 (en) 2008-02-28
CN104721168A (zh) 2015-06-24
JP2010501511A (ja) 2010-01-21
IL197129A (en) 2014-08-31
BRPI0716436B8 (pt) 2021-05-25
JP5220746B2 (ja) 2013-06-26
WO2008022932A2 (en) 2008-02-28
EP2056797A2 (en) 2009-05-13
PE20080738A1 (es) 2008-08-05
BRPI0716436A2 (pt) 2014-03-04
ZA200810781B (en) 2009-10-28
US8512748B2 (en) 2013-08-20
IL197129A0 (en) 2009-11-18
CO6150131A2 (es) 2010-04-20
NO20090100L (no) 2009-04-23
US20080069873A1 (en) 2008-03-20
WO2008022932A3 (en) 2008-07-24
TW200817053A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
NZ728442A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
DK1509521T3 (da) 1H-Imidazol[4,5-c]quinolinderivater til behandling af proteinkinaseafhænige sygdomme
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2005032567A3 (en) Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
WO2008061226A3 (en) Sustained-release formulations of topiramate
NO20075136L (no) Nye liposompreparater
WO2008146178A3 (en) A novel tablet dosage form
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
JP2010518086A5 (ru)
ATE525065T1 (de) Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
ATE286387T1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
MX341015B (es) Forma de dosificacion de liberacion extendida.
WO2006060325A3 (en) Coated drug delivery formulations
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
EA200300110A1 (ru) Композиция элетриптана в виде частиц
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
FR2854159B1 (fr) Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества